Pfizer withdrew its sweetened bid for AstraZeneca on Monday, ending a takeover saga that began back in January. The pharmaceutical giant's most recent bid for AstraZeneca, valued at £69.4 billion, or $117 billion, had received a mixed response from shareholders. Some critics looked down upon Pfizer's intentions to move its tax domicile to the U.K. from the U.S. following a transaction. Pfizer can't come back with another bid for AstraZeneca for six months, but the company is allowed to begin discussions in three months if the target initiates it.
Stock quotes in this video: